Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Specialty Drug Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy N/A

    Specialty and High-Cost Prescription Drug Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all healthspring policy alerts

    Know when healthspring releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part D prior authorization requirements for selected specialty and high-cost prescription drugs, including covered indications, clinical documentation, prescriber qualifications, prerequisites, exclusions, and authorization durations.

    Policy Summary
    PayerHealthSpring
    PolicySpecialty and High-Cost Prescription Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit diagnosis, supporting clinical documentation, prior-treatment history, and applicable biomarker or laboratory evidence with each authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    Drug-specific prior authorization criteria revised on October 5, 2027.

    8Drug policies represented
    11Affected product names
    3 mo–1 yrCoverage durations
    18+Common minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    YesPending CMS reviews
    YesPrior authorization required

    Coverage Criteria

    ABRYSVO through Arikayce

    Covered when the applicable product-specific criteria below are met.

    PRODUCT-SPECIFIC CRITERIA

    • ABRYSVO

      • All FDA-approved indications; non-pregnant individual is age 60 years or older, or age 18–59 years and at increased risk for lower respiratory tract disease; or pregnant individual is 32–36 weeks gestational age; patient has not already received an RSV vaccine.Coverage duration: 3 months
    • Acitretin

      • Diagnosis documented. For initial psoriasis therapy, patient has tried and failed, is intolerant of, or has a contraindication to methotrexate or cyclosporine.
      • For continuation, patient has already been started on therapy.Coverage duration: 12 months
    • ACTIMMUNE

      • Chronic granulomatous disease confirmed by molecular genetic testing identifying a pathogenic gene-related variant; or severe malignant osteopetrosis confirmed by radiographic skeletal findings or molecular genetic testing identifying a pathogenic gene-related variant.
      • For chronic granulomatous disease, prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist; for malignant osteopetrosis, prescribed by or in consultation with an endocrinologist or appropriate specialist.Coverage duration: 1 year
    • Adalimumab products (HADLIMA)

      • Diagnosis is documented. Initial-therapy age requirements: Crohn disease age 6 years or older; ulcerative colitis age 5 years or older; ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, plaque psoriasis, pyoderma gangrenosum, sarcoidosis, scleritis, sterile corneal ulceration, and non-radiographic axial spondyloarthritis age 18 years or older. Initial therapy requires specialist consultation appropriate to the diagnosis and preferred-product/prerequisite therapy as applicable. Coverage is subject to CMS review.Coverage duration: end of plan year
    • AKEEGA

      • Metastatic castration-resistant or metastatic castration-sensitive prostate cancer; patient has a BRCA mutation; medication is used with prednisone; and patient concurrently receives a GnRH analog or has had bilateral orchiectomy.Age 18 years or older; coverage duration: 1 year
    • ALDURAZYME

      • Diagnosis of mucopolysaccharidosis type I is confirmed by deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum, or by molecular testing demonstrating biallelic pathogenic or likely pathogenic variants. Prescribed by or in consultation with a geneticist, endocrinologist, metabolic-disorder specialist, or lysosomal-storage-disorder specialist.Coverage duration: 1 year
    • Alecensa

      • NSCLC: adjuvant therapy after resection for tumors at least 4 cm or node-positive, or advanced/metastatic disease, with ALK-positive disease. Anaplastic large cell lymphoma: ALK-positive and palliative-intent, relapsed, or refractory disease. Erdheim-Chester disease: ALK rearrangement/fusion-positive. Inflammatory myofibroblastic tumor: ALK-positive and advanced, recurrent, metastatic, or inoperable. Large B-cell lymphoma: ALK-positive and relapsed/refractory. Pediatric diffuse high-grade glioma: age 21 years or younger, ALK-positive, and adjuvant therapy excluding diffuse midline glioma/H3 K27-altered/pontine tumors, or recurrent/progressive disease.NSCLC and other adult indications: age 18 years or older; pediatric diffuse high-grade glioma: age 21 years or younger; coverage duration: 1 year
    • Alosetron

      • Diagnosis documented and patient is age 18 years or older.Coverage duration: 12 months
    • Prolastin-C

      • All FDA-approved indications; patient is age 18 years or older. Coverage remains subject to CMS review.
    • Alunbrig

      • Erdheim-Chester disease: ALK rearrangement/fusion-positive. Inflammatory myofibroblastic tumor: ALK-positive and advanced, recurrent, metastatic, or inoperable. NSCLC: ALK-positive by an approved test and advanced/metastatic; new patients must first try Alecensa, Ensacove, or Lorbrena. Peripheral T-cell lymphoma: ALK-positive anaplastic large cell lymphoma.Age 18 years or older; coverage duration: 1 year
    • Ambrisentan

      • Diagnosis documented and prescribed by or in consultation with a cardiologist or pulmonologist. Coverage subject to CMS review.Coverage duration: 1 year
    • ANKTIVA

      • Initial non-muscle-invasive bladder cancer therapy: all required—high-risk BCG-unresponsive disease, carcinoma in situ, and use in combination with BCG. Initial patient is age 18 years or older; prescribed by or in consultation with an oncologist or urologist.Initial duration: 6 months; maintenance duration: 3 months
    • Amphotericin B and amphotericin B liposome

      • All medically accepted indications. A Part B versus Part D coverage determination is made during review.Coverage duration: 6 months
    • ARCALYST

      • DIRA initial therapy: all required—patient weighs at least 10 kg, genetic testing confirms biallelic pathogenic IL1RN variants, and patient had clinical benefit with subcutaneous anakinra.
      • Pericarditis indication requires recurrent pericarditis.
      • Continuation for all indications requires a positive response to therapy.CAPS/pericarditis initial age: 12 years or older
    • AREXVY

      • Patient is age 60 years or older, or age 18–59 years and at increased risk for lower respiratory tract disease; patient has not already received an RSV vaccine.Coverage duration: 3 months
    • ARIKAYCE

      • Initial MAC lung disease therapy: all required—positive MAC sputum culture, MAC isolate susceptible to amikacin, and use with a background multidrug regimen such as a macrolide, ethambutol, and rifamycin. Initial therapy is for age 18 years or older and requires pulmonologist, infectious-disease physician, or MAC specialist involvement.
      • Continuation: use with a background multidrug regimen and either cultures have not converted or negative sputum cultures have been achieved for less than 12 months.

    Paliperidone through Cystaran

    Covered when the applicable diagnosis, age, specialist, laboratory, and prior-treatment requirements are met.

    PRODUCT-SPECIFIC CRITERIA

    • Paliperidone

      • Patient has tried two of olanzapine, quetiapine, risperidone, or ziprasidone; paliperidone ER for schizoaffective disorder may be approved without those trials.Coverage duration: 1 year
    • Augtyro

      • NSCLC: locally advanced or metastatic ROS1-positive disease detected by an approved test. Solid tumor: NTRK gene-fusion positive and locally advanced/metastatic or resection would likely cause severe morbidity. Pediatric diffuse high-grade glioma: NTRK fusion-positive and used as adjuvant therapy or for recurrent/progressive disease.NSCLC: age 18 years or older; solid tumors: age 12 years or older; pediatric glioma: younger than 18 years; coverage duration: 1 year
    • AVMAPKI-FAKZYNJA

    Cystaran through Everolimus

    Covered when the applicable initial, continuation, diagnostic, age, laboratory, specialist, and prerequisite requirements are met.

    PRODUCT-SPECIFIC CRITERIA

    • Dalfampridine

      • Initial: ambulatory patient with MS, impaired ambulation objectively documented, and use to improve or maintain mobility. Continuation: ambulatory MS patient benefiting from therapy. Neurologist or MS-specialist consultation required.Age 18 years or older; coverage duration: 1 year
    • Deferasirox

      • Transfusion-related chronic iron overload: regular transfusions and baseline serum ferritin greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia: baseline ferritin greater than 300 mcg/L. Continuation requires documented benefit and hematologist consultation.Coverage duration: 1 year
    • Droxidopa

    FRUZAQLA through Imdelltra

    Covered when the applicable oncology, molecular, disease-status, age, specialist, and treatment-history requirements are met.

    PRODUCT-SPECIFIC CRITERIA

    • FRUZAQLA

      • Colon, rectal, or appendiceal cancer that is advanced or metastatic and previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.Age 18 years or older; coverage duration: 1 year
    • GAVRETO

      • NSCLC: advanced/recurrent/metastatic RET fusion-positive disease detected by an FDA-approved test. Differentiated thyroid cancer: unresectable/recurrent/metastatic RET fusion- or mutation-positive disease requiring systemic therapy and radioactive-iodine-refractory papillary/follicular disease or oncocytic carcinoma. Anaplastic or medullary thyroid cancer: unresectable/recurrent/metastatic disease with RET pathogenic variant.NSCLC age 18 years or older; thyroid cancer age 12 years or older; coverage duration: 1 year

    Initial Therapy Criteria

    Acitretin through Brukinsa initial therapy

    Initial authorization requires the applicable diagnosis, molecular or laboratory confirmation, age, specialist, and prerequisite-treatment criteria.

    Acitretin: For psoriasis, methotrexate or cyclosporine has been tried and failed, is contraindicated, or is not tolerated.
    AKEEGA: Age 18 years or older; metastatic castration-resistant or castration-sensitive prostate cancer; BRCA mutation; use with prednisone; and concurrent GnRH analog or prior bilateral orchiectomy.
    Alecensa: The applicable ALK-positive or ALK rearrangement/fusion-positive disease, stage, and treatment-setting criteria are met.
    Alunbrig: ALK-positive advanced/metastatic NSCLC detected by an approved test and prior Alecensa, Ensacove, or Lorbrena trial for new-to-therapy patients.

    Continuation and Maintenance Criteria

    Continuation and maintenance criteria

    Continuation or maintenance authorization requires ongoing therapy, documented response or benefit, qualifying disease status, and the applicable authorization period.

    Acitretin continuation: Patient has already been started on acitretin.
    Anktiva maintenance: Maintenance therapy remains subject to prior authorization and the applicable Part B versus Part D determination.3-month authorization
    Arcalyst continuation: Patient has had a positive response to therapy.
    Arikayce continuation:

    Prerequisite and Step Therapy

    DrugIndication / useRequired prior therapy or sequenceExceptions / combination requirements
    AcitretinInitial psoriasis therapyTrial and failure of methotrexate or cyclosporine, or documented contraindication or intoleranceContinuation is allowed when the patient has already started acitretin
    AlunbrigNew-to-therapy patients with advanced or metastatic ALK-positive NSCLCTrial of Alecensa, Ensacove, or Lorbrena before AlunbrigPrior ALK-inhibitor therapy applies to new-to-therapy patients
    ArcalystDeficiency of interleukin-1 receptor antagonist (DIRA)Prior subcutaneous anakinra therapy with clinical benefitRequired before Arcalyst coverage for DIRA
    ArikayceMAC lung diseaseUse with a background multidrug regimenExample regimen: macrolide such as azithromycin or clarithromycin, ethambutol, and rifamycin such as rifampin or rifabutin
    PaliperidoneMost covered indicationsTrial of two of olanzapine, quetiapine fumarate, risperidone, or ziprasidonePaliperidone ER for schizoaffective disorder may be approved without those trials
    Avmapki-FakzynjaRecurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancerAt least one prior systemic therapyExamples include paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane
    AyvakitGISTTrial of two of Gleevec (imatinib), Sutent (sunitinib), Stivarga (regorafenib), or Qinlock (ripretinib)Prior therapy is not required when the tumor has a PDGFRA exon 18 mutation
    BosulifPhiladelphia chromosome-positive acute lymphoblastic leukemiaAt least one prior tyrosine kinase inhibitorThe prior-treatment requirement is specific to the Ph-positive ALL pathway
    BrukinsaFollicular lymphomaAt least two prior systemic regimensMust be used in combination with Gazyva (obinutuzumab)
    BrukinsaMantle cell lymphomaAt least one prior systemic regimenAlternative pathways include chemotherapy ineligibility, combination with rituximab, or TP53-mutated disease with Venclexta and Gazyva induction
    BrukinsaMarginal zone lymphomaAt least one prior systemic regimenNo additional combination requirement is specified
    BrukinsaPrimary central nervous system lymphomaAt least one prior systemic regimenMust be used with autologous stem cell reinfusion
    CAMCEVIProstate cancerTrial of Orgovyx or EligardPart B versus Part D determination occurs during review
    CALQUENCEMantle cell lymphoma, marginal zone lymphoma, or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomaGenerally at least one prior systemic regimenMantle cell lymphoma may qualify with chemotherapy ineligibility or combination with rituximab; Waldenstrom/lymphoplasmacytic lymphoma may qualify with combination with rituximab
    CopiktraChronic lymphocytic leukemia or small lymphocytic lymphomaAt least one BTK inhibitor and at least one BCL-2 inhibitorExamples: ibrutinib, zanubrutinib, acalabrutinib, or pirtobrutinib; and venetoclax
    DaurismoCovered indicationsPrerequisite therapy is requiredThe specific prerequisite is not identified in the policy excerpt
    BOMYNTRADenosumab non-osteoporosis indicationsPrerequisite therapy is requiredThe specific prerequisite is not identified; criteria are pending CMS review
    DrugIndication / useRequired prior therapy or sequenceExceptions / combination requirements
    DroxidopaSymptomatic neurogenic orthostatic hypotensionTrial of midodrine before droxidopaApplies to NOH due to a qualifying autonomic disorder
    EnbrelRheumatoid arthritis, ankylosing spondylitis, or JIA/JRATrial of one preferred adalimumab product; a non-preferred adalimumab trial also countsPreferred adalimumab product is Hadlima
    EnbrelBehcet's diseaseTrial of at least one conventional therapy, adalimumab, or infliximabConventional therapies include systemic corticosteroid, immunosuppressant, interferon alfa, or mycophenolate
    EnbrelChronic graft-versus-host diseaseTrial of a listed prior optionOptions include Rezurock, Niktimvo, Jakafi, or Imbruvica
    Entyvio PenUlcerative colitis or Crohn's diseaseTrial of two specified alternativesAlternatives vary by disease and include preferred or qualifying non-preferred adalimumab, infliximab, or ustekinumab products, Skyrizi, Tremfya, or Rinvoq
    Entyvio PenUlcerative colitis or Crohn's diseaseCurrent Entyvio IV therapy or IV induction within two months of starting subcutaneous therapyThis IV pathway is an alternative to the two-prior-therapy requirement
    EverolimusIndication-specific oncology usesPrior treatment depends on indication: endocrine therapy for HR-positive/HER2-negative breast cancer; systemic therapy for qualifying RCC, WM/LPL, and uterine sarcoma; or two listed drugs for GISTThymoma or thymic carcinoma requires prior chemotherapy or inability to tolerate chemotherapy; other combination requirements may apply
    ErivedgeSpecified basal cell carcinoma or medulloblastoma usesPrior chemotherapy is required for the specified medulloblastoma pathwayOther disease-specific conditions, including radiation, surgery, or resectability, may apply
    ErlotinibSpecified cancer indicationsPrior therapy is required for chordomaOther pathways require disease-specific stage, mutation, or combination therapy, including gemcitabine for pancreatic cancer and bevacizumab for specified RCC
    FASENRA / FASENRA PENFDA-approved indicationsPrerequisite therapy is requiredSpecific prerequisite is not identified in the policy excerpt
    FILSpariFDA-approved indicationsPrerequisite therapy is requiredDo not combine with specified renin-angiotensin-aldosterone, endothelin receptor, aliskiren, or other IgA-nephropathy therapies
    FINTEPLAFDA-approved indicationsPrerequisite therapy is requiredInitial therapy requires neurologist involvement and age 2 years or older
    FOTIVDAFDA-approved indicationsPrerequisite therapy is requiredDiagnosis and other therapies must be documented; specific prerequisite is not identified
    FRUZAQLAAdvanced or metastatic colon, rectal, or appendiceal cancerPrior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; prerequisite therapy is also requiredExamples of fluoropyrimidine therapy include 5-fluorouracil
    GILOTRIFCovered NSCLC or head and neck cancer pathwaysPrerequisite therapy is required; disease-specific prior therapy includes platinum-based chemotherapy for metastatic squamous NSCLC or non-nasopharyngeal head and neck cancerFor MA-PD beneficiaries, Part B must precede Part D step therapy
    GILOTRIFMA-PD beneficiariesComplete the Part B prerequisite before Part D step therapyThis sequencing rule applies only to beneficiaries enrolled in an MA-PD plan
    PromethazineTreatment of emesisTrial of a prescription oral antiemeticQualifying examples: ondansetron, granisetron, dolasetron, or aprepitant
    HyrnuoLocally advanced or metastatic NSCLCAt least one prior systemic therapyTumor must have an activating HER2/ERBB2 mutation
    IclusigGISTTry imatinib, then sunitinib, regorafenib tablets (Stivarga), and ripretinib tablets (Qinlock)All four therapies are required before Iclusig
    ImatinibPVNS/TGCTTrial of Turalio or RomvimzaThe prescriber may document that the patient cannot take either therapy
    ImatinibChronic graft-versus-host diseaseAt least one conventional systemic treatment, such as ImbruvicaAt least one prior systemic treatment is required
    ImatinibCutaneous melanomaAt least one prior systemic regimenDisease must also meet the applicable melanoma criteria
    ImkeldiFormulation-specific useTrial of brand or generic imatinib tabletsTablets must be dispersed in water or apple juice according to product labeling

    Prior Authorization and Provider Requirements

    Prior Authorization

    Early Product Set: Authorization, Eligibility, and Required Evidence

    Obtain prior authorization before dispensing the early products below. Submit the diagnosis, applicable age and prescriber qualifications, treatment history, required laboratory or molecular evidence, and requested coverage duration; unresolved CMS review or an incomplete record may delay or prevent approval.

    • ABRYSVO: age 60 years or older, or age 18–59 with increased risk for lower respiratory tract disease; pregnant patients must be 32–36 weeks' gestation; confirm no prior RSV vaccination. Coverage is 3 months.
    • Acitretin: document psoriasis diagnosis and prior methotrexate or cyclosporine trial, contraindication, or intolerance; continuation requires that treatment has already been started. Coverage is 12 months.
    • ACTIMMUNE: document chronic granulomatous disease by molecular genetic testing showing a pathogenic variant, or severe malignant osteopetrosis by characteristic radiographs or molecular testing; use the required immunology, hematology, infectious-disease, or endocrinology specialist.
    • Adalimumab products (HADLIMA, including PUSHTOUCH and CF presentations): submit diagnosis and prerequisite therapy; initial therapy is age- and indication-specific and requires the applicable specialist. Coverage is subject to pending CMS review and generally runs through the plan year.
    • ADEMPAS: cardiologist or pulmonologist involvement is required; do not combine with pulmonary-hypertension PDE-5 inhibitors or another soluble guanylate cyclase stimulator.

    Operational Thresholds and Required Documentation Values

    Operational thresholds
    Arcalyst DIRA minimum weightAt least 10 kg
    Arcalyst CAPS/pericarditis initial age12 years of age or older
    Arexvy age eligibility60 years of age or older, or adults aged 18 through 59 years at increased risk for lower respiratory tract disease
    Arikayce continuation culture statusNegative sputum cultures for MAC for less than 12 months, or cultures not yet negative
    Ayvakit systemic mastocytosis platelet countGreater than or equal to 50,000/mcL
    Chemet pretreatment blood lead levelGreater than 45 mcg/dL
    Deferasirox: transfusion-related chronic iron overload

    Authorization Durations

    Authorization durations
    GILOTRIFAuthorization for 1 year
    GLATIRAMER / GLATOPAAuthorization for 1 year
    TRULICITY, OZEMPIC, RYBELSUS, MOUNJAROAuthorization for 1 year
    GOMEKLIAuthorization for 1 year
    GENOTROPIN / GENOTROPIN MINIQUICKIdiopathic short stature: 6 months initial authorization and 12 months continuation; short bowel syndrome: 1 month; other indications: 12 months
    HAEGARDAAuthorization for 1 year
    HARVONIDuration consistent with AASLD guidance and inclusive of treatment already received for the requested drug

    Site-of-Care Requirements

    Billing Rule

    EYLEA requires ophthalmologist administration or supervision

    Obtain prior authorization for EYLEA and ensure the drug is administered by or under the supervision of an ophthalmologist. The request must include the diagnosis and is subject to a Part B versus Part D coverage determination.

    • Administration site: office.
    • Coverage duration: 1 year.
    • Applies to all FDA-approved indications.
    Policy Summary
    PayerHealthSpring
    PolicySpecialty and High-Cost Prescription Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit diagnosis, supporting clinical documentation, prior-treatment history, and applicable biomarker or laboratory evidence with each authorization request.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Maintenance CriteriaPrerequisite and Step TherapyPrior Authorization and Provider RequirementsOperational Thresholds and Required Documentation ValuesAuthorization DurationsSite-of-Care Requirements
    • Recurrent low-grade ovarian, fallopian-tube, or primary peritoneal serous cancer with a KRAS mutation and at least one prior systemic therapy.Age 18 years or older; coverage duration: 1 year
  1. Ayvakit

    • GIST: PDGFRA exon 18 mutation or trials of two of imatinib, sunitinib, regorafenib, or ripretinib. Myeloid/lymphoid neoplasm with eosinophilia: PDGFRA D842V mutation. Systemic mastocytosis: platelet count at least 50,000/mcL and indolent or qualifying advanced systemic mastocytosis subtype.
  2. Balversa

    • Urothelial carcinoma: susceptible FGFR3 alteration and subsequent therapy. Pancreatic adenocarcinoma: FGFR alteration, locally advanced/recurrent/metastatic disease, and subsequent therapy. NSCLC: metastatic disease with FGFR mutation/fusion. Breast cancer: stage IV disease, subsequent therapy, and FGFR1–3 alteration. Cholangiocarcinoma: unresectable, gross residual, or metastatic disease with FGFR2 fusion/rearrangement and subsequent therapy. Glioma: recurrent/progressive disease with FGFR alteration. Head and neck cancer: recurrent unresectable/metastatic disease, subsequent therapy, and FGFR alteration.Age 18 years or older; coverage duration: 1 year
  3. Benlysta

    • Lupus nephritis initial: biopsy-confirmed lupus nephritis and concurrent immunosuppressive regimen. Lupus nephritis continuation: concurrent immunosuppressive regimen and response to Benlysta. SLE initial: autoantibody-positive disease (ANA, anti-dsDNA, or anti-Smith) and concurrent standard therapy unless significant toxicity prevents it. SLE continuation: concurrent standard therapy and response/benefit. Appropriate rheumatology, immunology, nephrology, neurology, or dermatology consultation is required.Initial age: 5 years or older; coverage duration: 1 year
  4. Bexarotene

    • Cutaneous T-cell lymphoma with cutaneous manifestations/lesions, or primary cutaneous B-cell lymphoma treated with skin-directed therapy. Prescribed by or in consultation with an oncologist or dermatologist.Coverage duration: 1 year
  5. Bosulif

    • CML: Philadelphia-positive or BCR::ABL1-positive disease. Philadelphia-positive ALL: at least one prior tyrosine kinase inhibitor. Myeloid/lymphoid neoplasm with eosinophilia: qualifying diagnosis.General age: 15 years or older; myeloid/lymphoid neoplasm: 18 years or older; authorization: 12 months
  6. Brukinsa

    • Follicular lymphoma: at least two prior systemic regimens and use with obinutuzumab. CLL/SLL: diagnosis. Mantle cell lymphoma: prior systemic regimen, not a chemotherapy candidate, combination with rituximab, or TP53-mutated disease with venetoclax and obinutuzumab. Marginal zone lymphoma: at least one prior systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: diagnosis. Hairy cell leukemia: treated relapsed/refractory progressive disease. Primary CNS lymphoma: at least one prior systemic regimen and combination with autologous stem-cell reinfusion.Age 18 years or older; coverage duration: 1 year
  7. CABOMETYX

    • All FDA-approved and medically accepted oncology indications, including non-small-cell lung cancer, GIST, bone cancer, endometrial carcinoma, and adrenal-gland tumor; prerequisite therapy required and coverage subject to CMS review.
  8. CALQUENCE

    • CLL/SLL: diagnosis. Mantle cell lymphoma: prior systemic regimen or not a chemotherapy candidate, or combination with rituximab. Marginal zone lymphoma: at least one prior systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: at least one prior systemic regimen.Coverage duration: 1 year
  9. CAMCEVI

    • Prostate cancer or other medically accepted cancer indication. For prostate cancer, prescribed by or in consultation with an oncologist or urologist and patient must try Orgovyx or Eligard first. Part B versus Part D is determined during review.Coverage duration: 12 months
  10. CAMZYOS

    • All FDA-approved indications; initial and continuation patient is age 18 years or older and prerequisite therapy is required.
  11. CAPRELSA

    • All FDA-approved and medically accepted indications, including differentiated thyroid cancer (papillary, follicular, or oncocytic).
  12. Carglumic acid

    • NAGS: prescribed by a metabolic-disease specialist; without genetic testing, authorization is 3 months, and with genetic testing, 12 months. Other acute hyperammonemia indications may be approved for 7 days, including hyperammonemia due to propionic or methylmalonic acidemia.
  13. CAYSTON

    • Airway culture demonstrates Pseudomonas aeruginosa; prescribed by or in consultation with a pulmonologist, infectious-disease specialist, or cystic-fibrosis specialist.Coverage duration: 1 year
  14. CEREZYME

    • Type 1 Gaucher disease: deficient beta-glucocerebrosidase activity or biallelic pathogenic GBA variants. Type 3: same diagnostic confirmation and not used to manage neurologic manifestations. Do not use with another approved Gaucher therapy; specialist consultation required.Age 2 years or older; coverage duration: 1 year
  15. CHEMET

    • Acute lead poisoning, not prophylaxis; pretreatment blood lead level greater than 45 mcg/dL; patient age 12 months through 18 years; prescribed by or in consultation with a chelation specialist.Coverage duration: 2 months
  16. COPIKTRA

    • CLL/SLL: prior BTK inhibitor and BCL-2 inhibitor. Peripheral T-cell lymphoma: diagnosis. Breast implant-associated anaplastic large-cell lymphoma or hepatosplenic T-cell lymphoma: relapsed/refractory disease.Age 18 years or older; coverage duration: 1 year
  17. Cotellic

    • Unresectable advanced/metastatic melanoma with BRAF V600 mutation and combination with Zelboraf. CNS cancer: BRAF V600-positive disease with qualifying adjuvant, recurrent/progressive, or melanoma brain-metastasis use and combination with vemurafenib. Histiocytic neoplasm: Langerhans cell histiocytosis, Erdheim-Chester disease, or Rosai-Dorfman disease.Age 18 years or older; coverage duration: 1 year
  18. Cystaran

    • Corneal cysteine crystal deposits confirmed by slit-lamp examination; prescribed by or in consultation with an ophthalmologist or metabolic-disease specialist.Coverage duration: 1 year
    • Symptomatic neurogenic orthostatic hypotension due to primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, and prior trial of midodrine; cardiologist or neurologist consultation required.Age 18 years or older; coverage duration: 12 months
  19. Dupixent continuation

    • Continuation requires at least 6 months of therapy and beneficial response, disease-specific concurrent therapy when applicable: asthma with ICS; COPD with LABA/LAMA; CRSwNP with intranasal corticosteroid; EoE with improved eosinophilia or symptoms; prurigo nodularis, CSU, bullous pemphigoid, or AFRS with documented clinical response.Continuation duration: 1 year
  20. Doptelet

    • Diagnosis is documented. Doptelet Sprinkle is for patients younger than 6 years. Tablet age requirements: chronic/persistent ITP has no age restriction; thrombocytopenia associated with chronic liver disease requires age 18 years or older. Initial ITP therapy requires hematologist involvement.Chronic liver disease: 5 days; initial ITP: 14 weeks; continuation: 1 year
  21. ELAPRASE

    • Mucopolysaccharidosis II confirmed by deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum, or plasma, or molecular testing demonstrating pathogenic iduronate-2-sulfatase gene variants; specialist consultation required.Coverage duration: 1 year
  22. EMRELIS

    • Locally advanced or metastatic nonsquamous NSCLC; high c-Met protein overexpression, at least 50% of tumor cells with strong 3+ staining by an approved test; and at least one prior systemic therapy. Oncologist consultation and Part B versus Part D review required.Age 18 years or older; coverage duration: 1 year
  23. ENBREL

    • Initial age: ankylosing spondylitis/rheumatoid arthritis 18 years or older; JIA/PsA/Behcet disease 2 years or older; GVHD 6 years or older; plaque psoriasis 4 years or older. Initial therapy requires diagnosis-appropriate specialist consultation and preferred adalimumab trial for RA/JIA/JRA/AS, or required conventional therapy/adalimumab/infliximab trial for Behcet disease. Continuation requires prescriber-documented response. Preferred adalimumab is Hadlima.Coverage duration: end of plan year
  24. ENDARI

    • Sickle-cell disease; patient is age 5 years or older and prescribed by or in consultation with a sickle-cell specialist, such as a hematologist.Coverage duration: 1 year
  25. ENSACOVE

    • Non-small-cell lung cancer; patient is age 18 years or older.Coverage duration: 1 year
  26. Entyvio Pen

    • Ulcerative colitis initial: currently receiving Entyvio IV or will receive IV induction within 2 months, plus two qualifying biologic/JAK inhibitor trials or already started/undergoing IV induction. Crohn disease initial: currently receiving or initiating IV induction within 2 months, plus two qualifying preferred/nonpreferred biologic trials. Continuation: documented response. Avoid concurrent biologics or targeted synthetic DMARDs; initial gastroenterologist consultation required.Initial age: 18 years or older; continuation through end of plan year
  27. Epclusa and Harvoni

    • Hepatitis C treatment consistent with current AASLD/IDSA guidance; diagnosis documented; patient age 3 years or older; prescribed by or in consultation with gastroenterologist, hepatologist, infectious-disease physician, or liver-transplant physician. Do not combine with other direct-acting antivirals except ribavirin. Authorization includes treatment already received and follows guideline duration.
  28. Epidiolex

    • All FDA-approved indications and medically accepted refractory epilepsy indications; initial patient is age 1 year or older; prerequisite therapy required.
  29. Retacrit

    • Indication and duration are diagnosis-specific: chemotherapy-associated anemia 6 months; anemia with transfusion 1 month; CKD 1 year; myelofibrosis initial 3 months and continuation 1 year; other approved indications 1 year. MDS anemia requires age 18 years or older and hematologist/oncologist consultation. Coverage subject to CMS review.
  30. Everolimus

    • Breast cancer: recurrent/metastatic HR-positive, HER2-negative disease, prior endocrine therapy, appropriate menopausal/ovarian-suppression status, required combination with exemestane, fulvestrant, or tamoxifen, and no progression on everolimus. RCC: relapsed/stage IV non-clear-cell disease or clear-cell disease after one systemic therapy. TSC-associated SEGA requires intervention but cannot be curatively resected; TSC renal angiomyolipoma and partial-onset seizures qualify. Other covered oncology indications include thymoma/thymic carcinoma after or unable to tolerate chemotherapy, WM/LPL after systemic therapy, radioactive-iodine-refractory differentiated thyroid carcinoma, endometrial carcinoma with letrozole, GIST after prior therapy with combination as specified, pancreatic/GI/lung/thymic neuroendocrine tumors, PEComa or recurrent angiomyolipoma/lymphangioleiomyomatosis, relapsed/refractory classical Hodgkin lymphoma unsuitable for high-dose therapy/autologous rescue, qualifying histiocytic neoplasm with PIK3CA mutation, recurrent/progressive surgically inaccessible meningioma when radiation is not possible and combined with somatostatin analog or bevacizumab, and advanced/recurrent/metastatic/inoperable PEComa uterine sarcoma after systemic therapy.Coverage duration: 1 year
  31. Gefitinib

    • Advanced or metastatic NSCLC with EGFR mutation-positive disease detected by an approved test, including exon 19 deletion or exon 21 L858R; medically accepted use may include L861Q, G719X, or S768I.Age 18 years or older; coverage duration: 1 year
  32. GILOTRIF

    • Advanced/metastatic NSCLC with sensitizing EGFR mutation detected by an approved test, including exon 19 deletion, exon 21 L858R, L861Q, G719X, or S768I. Metastatic squamous NSCLC requires progression after platinum chemotherapy. Non-nasopharyngeal head and neck cancer requires progression on or after platinum chemotherapy. Part B step therapy applies to MA-PD beneficiaries.Age 18 years or older; coverage duration: 1 year
  33. Multiple sclerosis therapies

    • Dimethyl fumarate, glatiramer, and Glatopa require relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; neurologist/MS-specialist consultation; and no concurrent disease-modifying agent. Authorization is for 1 year.
  34. Glucagon-like peptide-1 agonists

    • Trulicity, Ozempic, Rybelsus, and Mounjaro require a documented diagnosis and are authorized for 1 year under the applicable FDA-approved indication.
  35. Neurofibromatosis type 1

    • Gomekli: patient has or had symptomatic plexiform neurofibromas before therapy and tumor is not amenable to complete resection.Age 2 years or older; coverage duration: 1 year
  36. Growth hormone therapy

    • Genotropin/Genotropin MiniQuick: approved FDA or medically accepted growth-hormone indications, including GHD, ISS, SGA, Noonan syndrome, Prader-Willi syndrome, SHOX deficiency, CKD, or SBS, with indication-specific age and endocrinology/nephrology consultation requirements. ISS: age 5 years or older, initial 6 months then 12-month continuation; SGA: age 2 years or older; SBS: 1 month; other indications: 12 months.
  37. Hereditary angioedema

    • Haegarda: hereditary angioedema or related qualifying disorder; prescribed by or in consultation with an allergist/immunologist or HAE specialist.Coverage duration: 1 year
  38. Tasimelteon

    • Non-24: patient is totally blind with no light perception and age 18 years or older. Smith-Magenis syndrome: age 3 years or older. Initial and continuation require neurologist or sleep-disorder specialist consultation.Initial duration: 6 months; continuation: 12 months
  39. Iclusig

    • Ph-positive or ABL-class translocation ALL: combination with chemotherapy, T315I-positive disease, or prior tyrosine kinase inhibitor. Ph-positive/BCR::ABL1-positive CML: T315I-positive disease, prior tyrosine kinase inhibitor, or accelerated/blast phase with no indicated alternative. GIST: prior imatinib, sunitinib, regorafenib, and ripretinib. Myeloid/lymphoid neoplasm with eosinophilia: ABL1 or FGFR1 rearrangement.All indications except ALL: age 18 years or older; coverage duration: 1 year
  40. IDHIFA

    • AML with IDH2 mutation-positive disease. Myelodysplastic syndrome with IDH2 mutation-positive disease and required prior therapy.Age 18 years or older; coverage duration: 1 year
  41. Imatinib and Imkeldi

    • CML: Philadelphia-positive or BCR::ABL1-positive disease. ALL: Philadelphia-positive or ABL-class translocation. Systemic mastocytosis: KIT D816V negative or unknown. Kaposi sarcoma: prior regimen with relapsed/refractory disease or KSHV-associated inflammatory cytokine syndrome. PVNS/TGCT: tried Turalio or Romvimza, or cannot take them. PDGFR-rearranged myelodysplastic/myeloproliferative disease. Chronic GVHD: prior conventional systemic treatment. Cutaneous melanoma: activating KIT mutation, metastatic/unresectable disease, and prior systemic regimen. Myeloid/lymphoid neoplasm with eosinophilia: ABL1, FIP1L1-PDGFRA, or PDGFRB rearrangement. Imkeldi requires a trial of imatinib tablets dispersed in water or apple juice.Indication-specific age requirements; most listed indications require age 18 years or older; coverage duration: 1 year
  42. IMBRUVICA

    • All FDA-approved and medically accepted indications, including chronic GVHD age 1 year or older and other indications generally age 18 years or older; prerequisite therapy required.
  43. IMDELLTRA

    • Primary progressive, relapsed, or refractory extensive-stage small-cell lung cancer after prior platinum-based chemotherapy; prescribed by or in consultation with an oncologist. Part B versus Part D determination is made during review.Age 18 years or older; coverage duration: 1 year
  44. Additional oncology products

    • Erivedge: locally advanced or metastatic basal-cell carcinoma, qualifying diffuse/genetic basal-cell carcinoma, or medulloblastoma with SHH-pathway mutation after chemotherapy. Erlotinib: EGFR-mutated advanced/metastatic NSCLC; stage IV/relapsed non-clear-cell RCC with advanced papillary disease and bevacizumab; chordoma after prior therapy; pancreatic cancer with gemcitabine; or advanced/recurrent/metastatic vulvar cancer. Other listed products—including Daurismo, Decnuapaz, Bomyntra, HERNEXEOS, HYRNUO, IBRANCE, IBTROZI, and products with pending CMS review—require the documented FDA-approved or medically accepted indication, applicable age and specialist requirements, and any stated prior therapy.Product-specific authorization durations apply
  45. High-risk medication and supply rules

    • Alcohol pads, gauze, and insulin syringes are covered when the prescriber confirms direct association with insulin delivery. For cyclobenzaprine, hydroxyzine, promethazine, and phenobarbital in older adults, documentation must establish the indication, specific benefit outweighing risk, monitoring for adverse effects, and assessment of anticholinergic risk; promethazine requires prior prescription antiemetic trial for emesis, and phenobarbital for seizures requires current use. Sedation/insomnia use of phenobarbital is not covered.Typical authorization duration: 12 months
  46. Anktiva: Age 18 years or older; high-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ; and combination use with BCG.
    Arcalyst: DIRA: weight at least 10 kg, bi-allelic pathogenic IL1RN variants, and prior clinical benefit with subcutaneous anakinra; or recurrent pericarditis.
    Arexvy: Age/risk criterion is met and the patient has not previously received an RSV vaccine.
    Arikayce: Positive MAC sputum culture, amikacin-susceptible isolate, and use with a background multidrug regimen.
    Paliperidone: Two specified prior antipsychotic trials; or paliperidone ER for schizoaffective disorder.
    Augtyro: ROS1-positive NSCLC, NTRK-fusion-positive solid tumor, or NTRK-fusion-positive pediatric diffuse high-grade glioma meeting age and disease-extent requirements.
    Avmapki-Fakzynja: Age 18 years or older; recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer; KRAS mutation; and at least one prior systemic therapy.
    Ayvakit: PDGFRA-mutated or previously treated GIST; PDGFRA D842V-positive eosinophilic neoplasm; or systemic mastocytosis with required subtype and platelet count.
    Balversa: Eligible FGFR-altered urothelial, pancreatic, lung, breast, biliary, glioma, or head-and-neck cancer meeting disease-status and subsequent-therapy criteria.
    Benlysta: Biopsy-confirmed lupus nephritis with concurrent immunosuppression; or autoantibody-positive SLE with concurrent standard therapy.
    Bosulif: Eligible CML, ALL, or eosinophilic neoplasm; Ph-positive ALL requires at least one prior tyrosine kinase inhibitor.
    Brukinsa: Eligible lymphoma or leukemia diagnosis with the disease-specific prior systemic therapy, combination therapy, relapse, or progression requirements.

    CAMZYOS through Epclusa initial therapy

    Initial authorization requires the applicable disease, age, diagnostic, specialist, laboratory, and guideline requirements.

    CAMZYOS: Patient is at least 18 years old and use is for an FDA-approved indication.
    CEREZYME/Cerezyme: Patient is at least 2 years old, has Type 1 or Type 3 Gaucher disease confirmed by enzyme or genetic testing, and has qualified specialist involvement; Type 3 use is not for neurological manifestations.
    Chemet: Acute lead poisoning; age 12 months through 18 years; pretreatment blood lead level greater than 45 mcg/dL; and chelation-specialist involvement.
    Clobazam: Patient is at least 2 years old, has an eligible seizure indication, and prerequisite therapy is satisfied.
    Cometriq: Patient is at least 18 years old, has an eligible indication, and prerequisite therapy is satisfied.
    Copiktra: Patient is at least 18 years old, has a qualifying hematologic malignancy, and meets the applicable prior-treatment requirements.
    Cosentyx: The indication-specific age and specialist requirements are met and prerequisite therapy is satisfied.
    Cotellic: Patient has a qualifying melanoma, CNS, or histiocytic-neoplasm indication and prerequisite therapy is satisfied.
    Cystaran: Slit-lamp examination confirms corneal cysteine crystal deposits and an ophthalmologist or metabolic-disease specialist prescribes or consults.
    Dalfampridine: Patient is ambulatory with multiple sclerosis, uses therapy to improve or maintain mobility, and has objectively documented impaired ambulation; specialist involvement is required.
    Deferasirox: Transfusion-related iron overload with ferritin greater than 1,000 mcg/L; or non-transfusion-dependent thalassemia with ferritin greater than 300 mcg/L.
    Doptelet: Applicable diagnosis, formulation-specific age requirement, prerequisite therapy, and hematologist involvement for initial ITP therapy are documented.
    Droxidopa: Age 18 years or older; symptomatic neurogenic orthostatic hypotension from an eligible cause; prior midodrine trial; and cardiologist or neurologist involvement.
    Emrelis: Locally advanced/metastatic nonsquamous NSCLC, c-Met overexpression of at least 50% with strong 3+ staining, and at least one prior systemic therapy.
    Enbrel: Indication-specific age and specialist requirements are met and required prior therapy is completed.
    Endari: Age at least 5 years and sickle-cell specialist involvement.
    Ensacove: Age 18 years or older and NSCLC diagnosis.
    Entyvio Pen: Patient is receiving Entyvio IV or will undergo IV induction within 2 months of subcutaneous initiation and meets the applicable two-therapy or IV-induction pathway.
    Epclusa: Age at least 3 years, specialist involvement, and use consistent with current AASLD/IDSA guidance.

    Epidiolex through Imdelltra initial therapy

    Initial authorization requires the disease-specific diagnosis, biomarker or molecular confirmation where applicable, age, prior treatment, and specialist requirements.

    Epidiolex: Patient is at least 1 year old, has an FDA-approved or medically accepted indication including refractory epilepsy, and prerequisite therapy is satisfied.
    Erivedge: Patient is at least 18 years old and meets the applicable BCC, medulloblastoma, or diffuse BCC disease criteria; prerequisite therapy is satisfied.
    Everolimus: Patient has a covered indication and meets the applicable prior-treatment, disease-status, biomarker, and combination requirements.
    FASENRA: Patient meets the asthma or EGPA age requirement, has an FDA-approved indication, has appropriate specialist involvement for asthma, and has prerequisite therapy.
    FILSpari: Patient has IgA nephropathy at age 18 years or older or FSGS at age 8 years or older, has nephrologist involvement, and has prerequisite therapy without a prohibited combination.
    FINTEPLA: Patient is at least 2 years old, has an FDA-approved indication, has neurologist involvement, and has prerequisite therapy.
    FOTIVDA: Patient is at least 18 years old, has an FDA-approved indication, diagnosis and other therapies are documented, and prerequisite therapy is satisfied.
    FRUZAQLA: Patient is at least 18 years old with an eligible colorectal or appendiceal cancer indication and the required prior chemotherapy; prerequisite therapy is satisfied.
    GAVRETO: Patient meets the applicable age and RET-positive disease pathway for NSCLC or thyroid cancer.
    Gefitinib: Patient is at least 18 years old with advanced/metastatic EGFR mutation-positive NSCLC detected by an approved test.
    GILOTRIF: Age 18 years or older and EGFR-positive advanced/metastatic NSCLC; metastatic squamous NSCLC after platinum progression; or non-nasopharyngeal head-and-neck cancer after platinum progression; prerequisite therapy applies.
    GLATIRAMER/GLATOPA: Qualifying relapsing multiple sclerosis, specialist involvement, and no concurrent MS disease-modifying therapy.
    GLP-1 agonists: Diagnosis supports an FDA-approved indication for TRULICITY, OZEMPIC, RYBELSUS, or MOUNJARO.
    GOMEKLI: Age at least 2 years, symptomatic plexiform neurofibromas present before treatment, and tumor not amenable to complete resection.
    GENOTROPIN: Applicable growth-hormone indication and indication-specific requirements are met.

    Criteria are pending CMS review.

    HAEGARDA: Applicable FDA-approved indication and allergist/immunologist or HAE-specialist involvement.

    Other criteria are pending CMS review.

    HARVONI: Age at least 3 years, guideline-consistent diagnosis and regimen, appropriate specialist involvement, and no prohibited direct-acting antiviral combination.
    Tasimelteon: Non-24 with total blindness/no light perception and age at least 18 years; or Smith-Magenis syndrome and age at least 3 years; with neurologist or sleep-specialist involvement.
    Iclusig: Eligible ALL, CML, GIST, or eosinophilic neoplasm pathway with required molecular findings and prior therapies.
    Idhifa: IDH2-positive AML; or IDH2-positive MDS with required prior therapy.
    Imatinib/Imkeldi: Applicable disease-specific chromosome, mutation, rearrangement, disease-status, and prior-treatment criteria are met; Imkeldi requires prior dispersed imatinib tablets.
    Imdelltra: Age 18 years or older; primary progressive, relapsed, or refractory extensive-stage SCLC after platinum-based chemotherapy; and oncologist involvement.
    Arikayce continues with the background multidrug regimen and the patient has not achieved negative MAC cultures or has been culture-negative for less than 12 months.
    Benlysta continuation: For lupus nephritis, continue immunosuppression and document response to prior Benlysta; for SLE, continue Benlysta with standard therapy.
    CAMZYOS continuation: Patient is at least 18 years old.
    Dalfampridine continuation: Patient remains ambulatory, uses therapy for mobility in multiple sclerosis, and benefits from or responds to therapy.
    Deferasirox continuation: Prescribing physician confirms benefit from therapy.
    Dupixent continuation: The indication-specific minimum prior-treatment period—generally at least 6 months—and beneficial response are documented, with required background therapy continued when applicable.Generally at least 6 months
    Enbrel continuation: Prescriber documents response to therapy.
    Entyvio Pen continuation: Patient has responded to therapy.
    Retacrit continuation: Continuation duration follows the indication: generally 1 year, chemotherapy-associated anemia 6 months, transfusion-associated use 1 month, and myelofibrosis continuation 1 year.
    Everolimus breast-cancer continuation: Patient has not experienced disease progression while receiving everolimus.
    Tasimelteon continuation: The applicable Non-24 or Smith-Magenis diagnosis and age requirements remain met, including total blindness/no light perception for Non-24, and neurologist or sleep-specialist involvement continues.Non-24: age 18 years or older; Smith-Magenis: age 3 years or older
  47. AIMOVIG: patient must be at least 18 years old; document migraine diagnosis and monthly headache frequency. Do not use with another CGRP inhibitor for migraine prevention; coverage is 1 year and pending CMS review.
  48. AKEEGA: document metastatic castration-resistant or castration-sensitive prostate cancer, BRCA mutation, prednisone combination, and concurrent GnRH analog or prior bilateral orchiectomy; age 18 years or older and prerequisite therapy apply.
  49. ALDURAZYME: geneticist, endocrinologist, metabolic-disorder, or lysosomal-storage specialist must document deficient alpha-L-iduronidase activity or biallelic pathogenic variants; coverage is 1 year.
  50. ALECENSA: document the disease-specific indication, age, ALK-positive status, and approved-test result. Failure to meet the applicable NSCLC, ALCL, Erdheim-Chester, inflammatory myofibroblastic tumor, large B-cell lymphoma, or pediatric glioma indication is a denial risk; coverage is 1 year.
  51. Alosetron: document diagnosis; patient must be at least 18 years old and authorization is 12 months.
  52. PROLASTIN-C: submit prior authorization with diagnosis and age 18 years or older; coverage is subject to pending CMS review.
  53. ALUNBRIG: document ALK status and the disease indication. New NSCLC therapy requires a trial of Alecensa, Ensacove, or Lorbrena; failure to meet ALK criteria or prerequisite therapy supports denial. Coverage is 1 year.
  54. Ambrisentan: submit diagnosis and cardiologist or pulmonologist involvement; prerequisite therapy and pending CMS review apply; coverage is 1 year.
  55. ANKTIVA: document high-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ and use in combination with BCG; initial therapy requires age 18 years or older and oncology/urology involvement. Part B versus Part D is determined during review; initial coverage is 6 months and maintenance 3 months.
  56. Amphotericin B, amphotericin B liposome, and liposomal amphotericin B: submit medically accepted indication and expect a Part B versus Part D determination; coverage is 6 months.
  57. Intravenous fluconazole: submit diagnosis; coverage is pending CMS review. Intravenous voriconazole: submit diagnosis; coverage is 3 months.
  58. Antineoplastic monoclonal antibodies: submit the diagnosis and administration details for products including Zirabev, L by nozyfic, Monjuvi, Zynlonta, Margenza, and Zynyz; Part B versus Part D review applies and coverage is 12 months.
  59. ARCALYST: document indication-specific criteria: DIRA requires weight at least 10 kg, biallelic IL1RN pathogenic variants, and clinical benefit with anakinra; pericarditis must be recurrent; continuation requires positive response. Pending CMS review and specialist review may apply.
  60. AREXVY: confirm age/risk criteria and no prior RSV vaccination; coverage is 3 months.
  61. ARIKAYCE: for initial MAC therapy, document positive sputum culture, amikacin-susceptible isolate, and concurrent background multidrug regimen; use a pulmonologist, infectious-disease physician, or MAC specialist. Continuation requires ongoing multidrug therapy and cultures not negative for 12 months; submit culture and medication history.
  62. BYSANTI and titration packs: submit prior authorization and document the medically accepted indication and prerequisite therapy.
  63. FANAPT and titration packs: submit prior authorization and document the medically accepted indication and prerequisite therapy; insufficient prior antipsychotic trials may result in denial.
  64. LYBALVI: submit indication and required prerequisite therapy.
  65. AUSTEDO, AUSTEDO XR, and titration kit: patient must be at least 18 years old; chorea due to Huntington disease requires neurologist involvement.
  66. AVMAPKI-FAKZYNJA: document recurrent low-grade ovarian, fallopian-tube, or primary peritoneal cancer, KRAS mutation, and at least one prior systemic therapy; failure to provide indication or prior systemic therapy supports denial.
  67. AYVAKIT: document GIST PDGFRA exon 18 mutation or two prior therapies (Gleevec, Sutent, Stivarga, or Qinlock), or the applicable PDGFRA D842V/systemic mastocytosis criteria; submit molecular, platelet, and disease-status evidence.
  68. BALVERSA: document diagnosis, FGFR alteration or fusion, disease stage, and subsequent-therapy status as applicable. Missing Balversa diagnosis, molecular documentation, or criteria supports denial; coverage is 1 year.
  69. BENLYSTA: document SLE or biopsy-confirmed lupus nephritis, autoantibody results where applicable, concurrent standard immunosuppressive therapy, and continuation response; required rheumatology, immunology, nephrology, neurology, or dermatology involvement and age 5 years or older apply.
  70. BESREMI: document diagnosis and hematologist/oncologist involvement; do not combine with another interferon product.
  71. BEXAROTENE: document diagnosis, cutaneous manifestations when applicable, and oncologist or dermatologist involvement.
  72. BOSULIF: document Ph-positive/BCR::ABL1-positive disease or the applicable myeloid/lymphoid neoplasm criteria; Ph-positive ALL requires a prior tyrosine-kinase inhibitor. Coverage is 12 months.
  73. BRAFTOVI: submit indication and prerequisite therapy; coverage is subject to prior authorization for approved and medically accepted uses.
  74. BRUKINSA: document diagnosis and prior systemic therapy. Follicular lymphoma requires at least two prior systemic regimens plus Gazyva; mantle-cell lymphoma requires the specified prior therapy, chemotherapy ineligibility, or approved combination; marginal-zone, hairy-cell, and primary CNS lymphoma criteria require the applicable prior treatment. Coverage is 1 year.
  75. CABOMETYX: submit indication, prior therapy, and specialist information; age and prescriber review may be pending CMS review. Authorization is required for approved and medically accepted uses, including NSCLC, GIST, bone cancer, endometrial carcinoma, and adrenal tumors.
  76. CALQUENCE: document the disease-specific indication and prior systemic therapy when required; failure to establish indication or prior therapy is a denial risk.
  77. CAMCEVI: document prostate-cancer diagnosis and oncology/urology involvement; Part B versus Part D is determined during review and prostate cancer requires prior Orgovyx or Eligard. Coverage is 12 months.
  78. CAMZYOS: patient must be at least 18 years old and meet the requested indication; age or indication failure supports denial.
  79. CAPRELSA: submit diagnosis and prior authorization for approved or differentiated-thyroid-cancer use.
  80. Carglumic acid: document metabolic disease and specialist involvement; NAGS cases require the stated genetic-test pathway and coverage may be 3 months or 7 days depending on documentation.
  81. CAYSTON: document diagnosis and Pseudomonas aeruginosa in an airway culture; pulmonologist, infectious-disease, cystic-fibrosis, or equivalent specialist involvement is required; coverage is 1 year.
  82. CEREZYME: document Gaucher diagnosis with deficient beta-glucocerebrosidase activity or biallelic GBA variants, specialist involvement, and age at least 2 years. Type 3 disease is covered only when treatment is not for neurologic manifestations; do not combine with another Gaucher-specific therapy.
  83. Chemet: patient must be 12 months through 18 years, have acute lead poisoning rather than prophylaxis, and have a pretreatment blood lead level greater than 45 mcg/dL; submit the level and chelation specialist documentation. Coverage is 2 months.
  84. Chorionic gonadotropin: submit prior authorization for the medically accepted indication; coverage is 12 months.
  85. Clobazam products and Sympazan: initial therapy requires age 2 years or older and prerequisite therapy; document refractory seizures or Dravet syndrome when applicable.
  86. Diabetic supplies, including alcohol pads, gauze, and insulin syringes: prescriber must attest that supplies are directly associated with insulin delivery; submit the diabetic-use attestation for the requested supply.
  87. Diclofenac: submit authorization and medically accepted indication; prerequisite therapy and pending CMS review apply.
  88. Dimethyl fumarate: document relapsing MS, including clinically isolated syndrome, relapsing-remitting, or active secondary progressive disease, and neurologist/MS-specialist involvement; prohibit concurrent MS disease-modifying therapy.
  89. Doptelet: document diagnosis and age-specific product criteria; chronic ITP initial therapy requires hematologist involvement, and coverage varies by indication and continuation.
  90. Droxidopa: document symptomatic neurogenic orthostatic hypotension due to an accepted cause, medication history, cardiology/neurology involvement, and a prior midodrine trial; coverage is 12 months.
  91. Duavee: submit authorization for the medically accepted indication and prerequisite therapy.
  92. Dupixent: submit diagnosis, age, specialist, concurrent therapy, and continuation response. Continuation generally requires at least 6 months of treatment plus documented beneficial response and the indicated background therapy; pending CMS review applies.
  93. Elaprase: document deficient iduronate-2-sulfatase activity or pathogenic gene findings, genetic/metabolic specialist involvement, and diagnostic testing; coverage is 1 year.
  94. Emrelis: document locally advanced/metastatic nonsquamous NSCLC, high c-Met overexpression (at least 50% strong 3+ staining by approved test), and at least one prior systemic therapy; Part B versus Part D is reviewed. Failure to meet NSCLC, biomarker, or prior-treatment criteria supports denial.
  95. Enbrel: submit diagnosis, prior therapies, concurrent medications, age, and appropriate specialist documentation. Initial RA/JIA/JRA/AS therapy generally requires a preferred adalimumab product, with Hadlima preferred; other indications require the specified conventional or targeted therapy. Continuation requires response.
  96. Endari: patient must be at least 5 years old and have sickle-cell disease; submit diagnosis and hematology/sickle-cell specialist information.
  97. Ensacove: document NSCLC diagnosis; coverage is 1 year.
  98. Entyvio Pen: document gastroenterologist involvement, current or planned IV induction within 2 months, and the required two preferred-agent trials or existing IV induction. Continuation requires response; do not combine with another biologic or targeted synthetic DMARD.
  99. Epclusa: patient must be at least 3 years old; submit diagnosis, specialist documentation, and AASLD/IDSA-guideline-supported regimen. Do not combine with other direct-acting antivirals except ribavirin.
  100. Epidiolex: initial therapy requires age 1 year or older and prerequisite therapy; document the approved epilepsy indication or refractory epilepsy.
  101. Documentation Required

    Cabometyx Through Imdelltra: Disease-Specific Authorization

    For oncology, specialty, and Part B/Part D products, the request must identify the disease subtype, biomarker or diagnostic result, prior treatment, combination regimen, and responsible specialist. Missing indication-specific evidence, failure of prerequisite therapy, or a pending CMS review can result in nonapproval.

    • RETACRIT: submit diagnosis and oncology/hematology documentation when required; coverage varies by chemotherapy, transfusion, CKD, myelofibrosis, and other indications.
    • ERIVEDGE: document locally advanced or metastatic BCC, qualifying surgery/radiation status or neoadjuvant use, or the applicable medulloblastoma/SHH mutation criteria and prior chemotherapy.
    • ERLEADA: submit diagnosis and prior authorization; coverage is subject to pending CMS review.
    • Erlotinib: document EGFR-mutated advanced/metastatic NSCLC, or the applicable RCC, chordoma, pancreatic, or vulvar cancer criteria; combination therapy and prior treatment must be shown where required.
    • Everolimus: submit diagnosis, HER2/HR status where applicable, molecular evidence, prior systemic/endocrine therapy, combination partner, and treatment history. Indication criteria differ across breast cancer, RCC, SEGA, angiomyolipoma, GIST, NET, sarcoma, lymphoma, thyroid, endometrial, meningioma, and other covered uses.
    • FOTIVDA: submit diagnosis and prior systemic therapies; coverage is 1 year.
    • FASENRA and FASENRA PEN: document asthma or EGPA, age, and allergist/immunologist/pulmonologist/rheumatologist involvement; pending CMS review and prerequisite therapy apply.
    • FILSpari: document IgAN or FSGS, age, nephrologist involvement, and clinical criteria; do not combine with ACE inhibitors, ARBs, other renin-angiotensin-aldosterone antagonists, endothelin receptor antagonists, aliskiren, Fabhalta, Vanrafia, or other IgAN therapies.
    • FRUZAQLA: document advanced or metastatic colon, rectal, or appendiceal cancer and prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
    • GAVRETO: document advanced/recurrent/metastatic disease and FDA-test-confirmed RET fusion or mutation; submit the biomarker report and indication-specific documentation.
    • Gefitinib: document advanced/metastatic EGFR-mutated NSCLC and approved-test results, including the qualifying mutation.
    • GILOTRIF: document sensitizing EGFR mutation and approved test for advanced/metastatic NSCLC; squamous NSCLC requires progression after platinum therapy, and head/neck cancer requires progression after platinum therapy. Part B must be reviewed before Part D where applicable.
    • GLATIRAMER/GLATOPA: document relapsing MS and neurologist/MS-specialist involvement; prohibit concurrent MS disease-modifying therapy.
    • GLP-1 agonists: for TRULICITY, OZEMPIC, RYBELSUS, and MOUNJARO, submit diagnosis and authorization request; each is generally authorized for 1 year and requires indication documentation.
    • GOMEKLI: patient must be at least 2 years old and have NF1 with symptomatic plexiform neurofibromas that were present before treatment and are not amenable to complete resection; missing disease or tumor-status evidence supports denial.
    • GENOTROPIN: submit diagnosis, endocrine/nephrology documentation, age and indication, and required medical information; coverage varies by indication, including ISS, SGA, GHD, CKD, Noonan, Prader-Willi, SHOX, and SBS.
    • HAEGARDA: submit HAE diagnosis and allergist/immunologist or HAE-specialist involvement; coverage is 1 year and pending CMS review.
    • HARVONI: patient must be at least 3 years old; submit HCV diagnosis, treatment history, specialist documentation, and AASLD/IDSA guideline support. Do not combine with other direct-acting antivirals except ribavirin; duration includes treatment already received.
    • HERNEXEOS: document unresectable or metastatic NSCLC and HER2/ERBB2 activating mutation; submit clinical and biomarker documentation. Failure to meet disease or biomarker criteria supports denial.
    • Tasimelteon: document Non-24 with total blindness/no light perception or the applicable Smith-Magenis syndrome indication, age, and sleep or neurology specialist involvement; authorization is 6 months initially and 12 months for continuation.
    • Cyclobenzaprine, hydroxyzine, promethazine, and phenobarbital: patients under 65 are generally approved; for patients 65 or older submit high-risk-medication documentation showing indication, specific benefit outweighing risk, monitoring plan, and anticholinergic-risk assessment. Promethazine for emesis also requires a prior oral antiemetic trial; phenobarbital for seizures requires current use, and sedation/insomnia is excluded.
    • HYRNUO: document locally advanced/metastatic NSCLC, HER2/ERBB2 activating mutation, and at least one prior systemic regimen; submit clinical, biomarker, and treatment history.
    • IBRANCE: submit disease-specific indication and prerequisite therapy for approved or medically accepted uses, including listed sarcoma and uterine/endometrial indications.
    • IBTROZI: submit diagnosis and authorization information for the requested approved indication.
    • ICATIBANT: submit HAE diagnosis and allergist/immunologist or HAE-specialist documentation; coverage is 1 year and pending CMS review.
    • ICLUSIG: report Ph status and T315I status for leukemia; document the applicable ALL/CML criterion. GIST requires prior imatinib, sunitinib, regorafenib, and ripretinib consistent with NCCN recommendations; ABL1/FGFR1 rearrangement evidence is required for the applicable myeloid/lymphoid neoplasm.
    • IDHIFA: document IDH2 mutation status and AML or MDS indication; MDS requires prior therapy as specified. Coverage is 1 year.
    • Imatinib: document disease-specific criteria, including Ph-positive/BCR::ABL1-positive CML or ALL, KIT/PDGFR-related disease, ABL1/FGFR1 or FIP1L1-PDGFRA/PDGFRB rearrangements, and the applicable mutation or disease evidence. PVNS/TGCT requires prior Turalio or Romvimza or documented inability to use them; chronic GVHD and melanoma require prior systemic therapy. Imkeldi requires a prior trial of dispersed imatinib.
    • IMBRUVICA: submit diagnosis, age, and prerequisite therapy; GVHD requires age 1 year or older, while other indications generally require age 18 years or older.
    • IMDELLTRA: document extensive-stage small-cell lung cancer that is primary progressive, relapsed, or refractory after platinum-based chemotherapy; oncologist involvement and Part B versus Part D review are required. Coverage is 1 year.
    Step Therapy

    Cross-Product Prerequisites and Exclusions

    Apply prerequisite therapy, age, specialist, combination, and coverage-channel rules before submitting. Requests that omit required trials, use prohibited combinations, or lack diagnostic and biomarker confirmation should be held for correction or denied under the applicable criterion.

    • Required step therapy: methotrexate or cyclosporine before acitretin; an approved ALK inhibitor before Alunbrig; anakinra before Arcalyst for DIRA; a background multidrug regimen for Arikayce; prior antipsychotic trials for paliperidone; prior systemic therapy for Avmapki-Fakzynja, Bosulif, Brukinsa, Copiktra, FOTIVDA, FRUZAQLA, Imdelltra, and applicable oncology products; prior Orgovyx or Eligard for CAMCEVI; prior midodrine for droxidopa; preferred adalimumab or other required biologic/conventional therapy for Enbrel; IV induction and two preferred-agent trials for Entyvio Pen; prior oral antiemetic for promethazine; and prior ALK/oncology therapy where specified.
    • Combination requirements: AKEEGA requires prednisone and GnRH suppression or orchiectomy; Anktiva requires BCG; Cotellic requires the indicated Zelboraf combination and BRAF V600 evidence; Arikayce requires a macrolide, ethambutol, and rifamycin background regimen; Benlysta requires concurrent standard therapy; Epclusa and Harvoni prohibit other direct-acting antivirals except ribavirin; Everolimus requires the applicable combination partner; GILOTRIF requires Part B before Part D where applicable.
    • Prohibited concurrent therapy: ADEMPAS with pulmonary-hypertension PDE-5 inhibitors or other soluble guanylate cyclase stimulators; AIMOVIG with another migraine-prevention CGRP inhibitor; Besremi with another interferon; dimethyl fumarate or glatiramer with another MS disease-modifying therapy; CEREZYME with another Gaucher therapy; Dupixent/Entyvio restrictions on concurrent biologics or targeted DMARDs as applicable; FILSPARI with prohibited renin-angiotensin, endothelin, aliskiren, or other IgAN agents; and Epclusa/Harvoni with prohibited antiviral combinations.
    • Part B versus Part D: perform the CMS channel review for amphotericin products, antineoplastic monoclonal antibodies, ANKTIVA, CAMCEVI, EMRELIS, GILOTRIF, and IMDELLTRA before finalizing authorization; pending CMS review or required specialist involvement is an operational denial or delay risk.
    • Age and specialist controls: verify the product-specific minimum age, including ABRYSVO pregnancy/age criteria, AIMOVIG age 18 or older, ANKTIVA initial age 18 or older, CAYSTON and rare-disease specialist involvement, CAMZYOS age 18 or older, EPIDIOLEX age 1 or older, FASENRA age by indication, tasimelteon age by indication, and high-risk medication review at age 65 or older.
    • Continuation therapy: document response or benefit for acitretin, Arcalyst, Benlysta, dalfampridine, deferasirox, Dupixent, Enbrel, Entyvio Pen, and other products with continuation criteria; continuation without response documentation is a denial risk.
    Denial Risk

    Documentation Checklist and Denial Prevention

    The request packet should contain enough evidence for a clinical reviewer to confirm diagnosis, indication, age, prior therapy, biomarker status, specialist oversight, and response. Missing diagnostic confirmation or supporting medical information is a common denial condition even when the product is otherwise listed for coverage.

    • Diagnostic evidence: provide genetic or laboratory confirmation for ACTIMMUNE, ALDURAZYME, CEREZYME, ELAPRASE, CYSTARAN, Chemet, carglumic acid, deferasirox, and rare metabolic disorders; provide culture results for CAYSTON and ARIKAYCE; provide slit-lamp confirmation for CYSTARAN; provide lead level for Chemet; and provide ferritin thresholds and response for deferasirox.
    • Oncology and biomarker evidence: include ALK status for Alecensa and Alunbrig; BRCA for AKEEGA; KRAS for Avmapki-Fakzynja; PDGFRA or other required mutation for Ayvakit; FGFR for Balversa; BRAF V600 for Cotellic; c-Met staining for Emrelis; EGFR for erlotinib, gefitinib, and Gilotrif; RET for Gavreto; HER2/ERBB2 for Hernexeos and Hyrnuo; IDH2 for Idhifa; Ph/T315I/ABL-class results for Iclusig; KIT/PDGFR findings for imatinib; and tumor status, stage, and prior-treatment records for all oncology requests.
    • Specialist documentation: identify the prescribing or consulting specialist for ACTIMMUNE, ALDURAZYME, ARCALYST, ARIKAYCE, BENLYSTA, BESREMI, BEXAROTENE, CAYSTON, CEREZYME, COSENTYX, DECNUPAZ, ELAPRASE, ENBREL, ENT YVIO, FASENRA, GENOTROPIN, HAEGARDA, HARVONI, ICATIBANT, IMDELLTRA, and other products with specialist restrictions.
    • Continuation and monitoring: provide prior authorization history, treatment dates, response measures, adverse-effect monitoring, and current regimen for Dupixent, dalfampridine, droxidopa, deferasirox, Benlysta, Entyvio Pen, Enbrel, and high-risk medications. For dalfampridine, include objective mobility assessment such as timed 25-foot walk or MS Walking Scale-12.
    • Clinical history: include migraine frequency for AIMOVIG, treatment history for Acitretin, Copiktra, FRUZAQLA, Harvoni, Ibrance, Iclusig, Idhifa, Imatinib, Imdelltra, and FOTIVDA; prior antipsychotic history for paliperidone; prior lymphoma therapy for Brukinsa; and prior systemic or platinum-based chemotherapy for oncology products.
    • Denial risks: missing diagnostic confirmation; failure to meet Alecensa indication criteria; failure to meet Alunbrig criteria or prerequisite therapy; pending CMS review or absent specialist documentation; failure to meet Anktiva initial criteria; absent RSV vaccination history or age/risk criteria; absent Arcalyst, Arikayce, Augtyro, Avmapki-Fakzynja, Ayvakit, Balversa, Benlysta, Besremi, Bexarotene, Bosulif, Brukinsa, CAYSTON, CEREZYME, Cotellic, Dupixent, Emrelis, Epclusa, Erivedge, Erlotinib, Everolimus, Filspari, Fruzaqla, Gavreto, Gilotrif, Gomekli, Harvoni, Hernexeos, Tasimelteon, Hyrnuo, Iclusig, Idhifa, Imatinib, or Imdelltra criteria; prohibited concurrent therapy; insufficient prior therapy; or unsupported off-label use.
    • Coverage duration and renewal: document the requested period and renewal evidence: 3 months for ABRYSVO/AREXVY, 6 months for amphotericin products and initial tasimelteon, 1 year for most specialty products, 12 months for acitretin and many oral products, and product-specific initial/maintenance periods for ANKTIVA, Dupixent, Doptelet, Retacrit, and Genotropin.
    Serum ferritin greater than 1,000 mcg/L before starting therapy
    Deferasirox: non-transfusion-dependent thalassemiaSerum ferritin greater than 300 mcg/L before starting therapy
    Dalfampridine impaired ambulation assessmentObjective measure such as the timed 25-foot walk or Multiple Sclerosis Walking Scale-12
    Emrelis c-Met tumor expressionGreater than or equal to 50 percent of tumor cells with strong [3+] staining
    Emrelis prior systemic therapyAt least 1 prior systemic therapy
    Entyvio alternative therapy trials2 prior therapies